Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CureVac (CVAC) Other Accumulated Expenses (2020 - 2024)

Historic Other Accumulated Expenses for CureVac (CVAC) over the last 5 years, with Q2 2024 value amounting to -$1106.0.

  • CureVac's Other Accumulated Expenses rose 4530.71% to -$1106.0 in Q2 2024 from the same period last year, while for Jun 2024 it was -$1106.0, marking a year-over-year increase of 4530.71%. This contributed to the annual value of $348911.2 for FY2021, which is 8562.67% down from last year.
  • Latest data reveals that CureVac reported Other Accumulated Expenses of -$1106.0 as of Q2 2024, which was up 4530.71% from -$600.76 recorded in Q1 2024.
  • CureVac's Other Accumulated Expenses' 5-year high stood at $2.4 million during Q4 2020, with a 5-year trough of -$3298.6 in Q1 2022.
  • For the 5-year period, CureVac's Other Accumulated Expenses averaged around $345706.0, with its median value being -$1171.2 (2023).
  • Per our database at Business Quant, CureVac's Other Accumulated Expenses plummeted by 8562.67% in 2021 and then surged by 6251.41% in 2023.
  • Over the past 5 years, CureVac's Other Accumulated Expenses (Quarter) stood at $2.4 million in 2020, then plummeted by 85.63% to $348911.2 in 2021, then crashed by 100.95% to -$3298.6 in 2022, then skyrocketed by 38.7% to -$2022.1 in 2023, then soared by 45.31% to -$1106.0 in 2024.
  • Its last three reported values are -$1106.0 in Q2 2024, -$600.76 for Q1 2024, and -$2022.1 during Q2 2023.